Cambridge Antibody Technology and Lonza Biologics announce long term Supply Agreement
Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) and Lonza Biologics (SWX: LONN.VX) today announce that they have signed a long term agreement for Lonza Biologics to manufacture and supply clinical grade antibody drugs to CAT for up to five years.
The agreement, which is effective immediately, builds on the existing close relationship between the companies and will guarantee that CAT has access to manufacturing capacity for both ongoing programmes and future projects.
Dr. David Chiswell, CAT’s CEO, commented “We are aware of some concern within the industry about manufacturing capacity. This agreement between CAT and Lonza Biologics ensures that CAT’s programmes will not be affected by supply problems, providing CAT, and its current and future partners, with a reliable supply of its antibodies, initially for clinical trials and potentially for commercial-scale supply. We believe that in planning for the future and reaching a commitment with Lonza Biologics in this way, we have chosen the best and most cost-effective way forward for CAT.”
Mr Larry Thomas, Vice-President Sales and Marketing of Lonza Biologics added “CAT are a long standing customer of Lonza Biologics. We are pleased that our existing relationship will be strengthened further by this long term agreement."
Other news from the department science
